Studies platelet-producing cells in people with sickle cell disease
Observes megakaryocytes, bone marrow cells that make platelets, in adults with sickle cell disease.
Plain-language title generated from the registry record
Registry title: Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
Key facts
- Where
- Toulouse, FranceSee the site
Where in France
- CHU de ToulouseToulouse, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT06887907
- Record updated
- 20 March 2025
- Original description
Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.Read full original descriptionShow less
Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.
Inclusion: Sickle cell disease SS or S-béta° thalassemia; Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome; Age > 18 years old.
Exclusion: Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23; Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome); Anti-platelets agents; Red blood cell exchange or transfusion < 3 months.